Inflammation-based factors and prognosis in patients with colorectal cancer

World Journal of Gastrointestinal Oncology

Volumn 7, Issue 8, 2015, Pages 111-117

  Maeda, Kiyoshi ^a   Shibutani, Masatusne ^a   Otani, Hiroshi ^a   Nagahara, Hisashi ^a   Ikeya, Tetsuro ^a   Iseki, Yasuhito ^a   Tanaka, Hiroaki ^a   Muguruma, Kazuya ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

C reactive protein; Colorectal cancer; Glasgow Prognostic Score; Inflammationbased factor; Neutrophil to lymphocyte ratio; Nutritional Prognostic Index; Platelet to lymphocyte ratio; Prognosis

Indexed keywords

EID: 84977597211     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v7.i8.111     Document Type: Article

References (56)

1. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398-2424 [PMID: 10820364 DOI: 10.1002/(SICI)1097-0142(20000515)88:10:2398:: AIDCNCR26>3.0.CO;2-I]
2. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321: 531-535 [PMID: 10968812 DOI: 10.1136/bmj.321.7260.531]
3. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID: 15051767 DOI: 10.1200/JCO.2004.11.037]
4. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930]
5. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]
6. Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 2012; 4: 75-89 [PMID: 22423266 DOI: 10.1177/1758834011431592]
7. Sobin L, Gospodarowicz M, Wittekind C. International against Cancer. TNM classification of malignant tumors, 7th ed. New York: Wiley-Blackwell, 2009: 73-77
8. Kang SM, Maeda K, Onoda N, Chung YS, Nakata B, Nishiguchi Y, Sowa M. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997; 74: 502-507 [PMID: 9355971 DOI: 10.1002/(SICI)1097-0215(199710 21)74:5<502::AID-IJC4>3.0.CO;2-7]
9. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, Yamashita Y, Onoda N, Kato Y, Nitta A, Arimoto Y. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 1995; 13: 477-481 [PMID: 7531224]
10. Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 2006; 29: 408-417 [PMID: 16891872 DOI: 10.1097/01. coc.0000221317.56731.4e]
11. Ilyas M, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999; 35: 335-351 [PMID: 10448282 DOI: 10.1016/S0959-8049(99)00298-1]
12. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003; 30: 3-14 [PMID: 12840796 DOI: 10.1016/S0093-7754(03)70010-4]
13. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99 [PMID: 19571295 DOI: 10.1056/NEJMc0904160]
14. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]
15. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-233 [PMID: 16603636 DOI: 10.1158/1541-7786.MCR-05-0261]
16. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 2014; 110: 1409-1412 [PMID: 24548867 DOI: 10.1038/bjc.2014.90]
17. Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, Klepstad P. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res 2013; 19: 5456-5464 [PMID: 23938289 DOI: 10.1158/1078-0432.CCR-13-1066]
18. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39: 534-540 [PMID: 22995477 DOI: 10.1016/j.ctrv.2012.08.003]
19. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998; 176: 335-338 [PMID: 9817250 DOI: 10.1016/S0002-9610(98)00204-9]
20. Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Mohri Y, Kusunoki M. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res 2013; 33: 5065-5074 [PMID: 24222151]
21. Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, Hirakawa K. Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer. Surg Today 2015; 45: 315-321 [PMID: 24817059 DOI: 10.1007/ s00595-014-0909-1]
22. Sugimoto K, Komiyama H, Kojima Y, Goto M, Tomiki Y, Sakamoto K. Glasgow prognostic score as a prognostic factor in patients undergoing curative surgery for colorectal cancer. Dig Surg 2012; 29: 503-509 [PMID: 23392422 DOI: 10.1159/000346002]
23. Kishiki T, Masaki T, Matsuoka H, Kobayashi T, Suzuki Y, Abe N, Mori T, Sugiyama M. Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer. Am J Surg 2013; 206: 234-240 [PMID: 23827511]
24. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Inflammation-based prognostic system predicts survival after surgery for stage IV colorectal cancer. Am J Surg 2013; 205: 22-28 [PMID: 23116639 DOI: 10.1016/j.amjsurg.2012.04.012]
25. Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, Hirakawa K. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res 2013; 33: 3291-3294 [PMID: 23898094]
26. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/ lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-1295 [PMID: 21448173 DOI: 10.1038/bjc.2011.100]
27. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, Lv Y. Prognostic role of neutrophilto- lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 2014; 134: 2403-2413 [PMID: 24122750 DOI: 10.1002/ijc.28536]
28. Nozoe T, Kohno M, Iguchi T, Mori E, Maeda T, Matsukuma A, Ezaki T. The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma. Surg Today 2012; 42: 532-535 [PMID: 22139087 DOI: 10.1007/s00595-011-0061-0]
29. Maeda K, Shibutani M, Otani H, Nagahara H, Sugano K, Ikeya T, Kubo N, Amano R, Kimura K, Muguruma K, Tanaka H, Hirakawa K. Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor. World J Surg 2014; 38: 1217-1222 [PMID: 24305937 DOI: 10.1007/s00268-013-2386-x]
30. Ikeya T, Shibutani M, Maeda K, Sugano K, Nagahara H, Ohtani H, Hirakawa K. Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer. J Cancer Res Clin Oncol 2015; 141: 307-313 [PMID: 25124497 DOI: 10.1007/s00432-014-1799-8]
31. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ, Lee JH. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012; 17: 216-222 [PMID: 22424597 DOI: 10.3109/1354750X.2012.656705]
32. Maeda K, Shibutani M, Otani H, Nagahara H, Sugano K, Ikeya T, Amano R, Kimura K, Sakurai K, Kubo N, Muguruma K, Tanaka H, Inoue T, Hirakawa K. Prognostic value of preoperative inflammation-based prognostic scores in patients with stage IV colorectal cancer who undergo palliative resection of asymptomatic primary tumors. Anticancer Res 2013; 33: 5567-5573 [PMID: 24324099]
33. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 2004; 49: 970-976 [PMID: 15309885 DOI: 10.1023/B:DDAS.0000034556.48527.6e]
34. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005; 11: 1639-1643 [PMID: 15786541 DOI: 10.3748/wjg.v11.i11.1639]
35. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’ Reilly DS, Foulis AK, Horgan PG, McMillan DC. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633-2641 [PMID: 21724383 DOI: 10.1016/j.ejca.2011.03.028]
36. Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T and Yanaga K. The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett 2012; 4: 324-328 [PMID: 22844378]
37. Zahorec R. Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14 [PMID: 11723675]
38. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009; 90: 222-231 [PMID: 19563607 DOI: 10.1111/j.1365-2613.2009.00641.x]
39. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71: 2411-2416 [PMID: 21427354 DOI: 10.1158/0008-5472.CAN-10-2583]
40. Huber C, Bobek N, Kuball J, Thaler S, Hoffarth S, Huber C, Theobald M, Schuler M. Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo. Cell Death Differ 2005; 12: 317-325 [PMID: 15678149 DOI: 10.1038/sj.cdd.4401563]
41. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer. J Surg Oncol 2012; 106: 887-891 [PMID: 22623286 DOI: 10.1002/jso.23163]
42. Monreal M, Fernandez-Llamazares J, Piñol M, Julian JF, Broggi M, Escola D, Abad A. Platelet count and survival in patients with colorectal cancer—a preliminary study. Thromb Haemost 1998; 79: 916-918 [PMID: 9609220]
43. Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-140 [PMID: 12714883 DOI: 10.1097/00000421-200304000-00007]
44. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725 [PMID: 11675343 DOI: 10.1182/blood.V98.9.2720]
45. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009; 197: 466-472 [PMID: 18639229 DOI: 10.1016/j.amjsurg.2007.12.057]
46. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012; 23: 265-273 [PMID: 23094130 DOI: 10.3802/jgo. 2012.23.4.2 65]
47. Delmore G. Assessment of nutritional status in cancer patients: widely neglected? Support Care Cancer 1997; 5: 376-380 [PMID: 9322349 DOI: 10.1007/s005200050095]
48. Watanabe M, Iwatsuki M, Iwagami S, Ishimoto T, Baba Y, Baba H. Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg 2012; 36: 1632-1639 [PMID: 22407085 DOI: 10.1007/s00268-012-1526-z]
49. Nozoe T, Kimura Y, Ishida M, Saeki H, Korenaga D, Sugimachi K. Correlation of pre-operative nutritional condition with postoperative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol 2002; 28: 396-400 [PMID: 12099649 DOI: 10.1053/ejso.2002.1257]
50. Boléo-Tomé C, Monteiro-Grillo I, Camilo M, Ravasco P. Validation of the Malnutrition Universal Screening Tool (MUST) in cancer. Br J Nutr 2012; 108: 343-348 [PMID: 22142968 DOI: 10.1017/ S000711451100571X]
51. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22: 415-421 [PMID: 12880610 DOI: 10.1016/S0261-5614(03)00098-0]
52. Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi 1984; 85: 1001-1005 [PMID: 6438478]
53. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491-497 [PMID: 7424938 DOI: 10.1016/S0149-2918(05)80001-3]
54. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O’Brien ME. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004; 90: 1905-1911 [PMID: 15138470 DOI: 10.1038/ sj.bjc.6601781]
55. Burden ST, Hill J, Shaffer JL, Todd C. Nutritional status of preoperative colorectal cancer patients. J Hum Nutr Diet 2010; 23: 402-407 [PMID: 20487172 DOI: 10.1111/j.1365-277X.2010.01070. x]
56. Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 1998; 11: 48-51 [PMID: 9876478 DOI: 10.1002/(SICI)1097-0215(1998)78: 11]